Bitcoin briefly fell below $81,000 before recovering to around $82,500, triggered by $1.09 billion in forced liquidations of leveraged crypto positions, mostly from traders betting on price increases. This sell-off added pressure on digital assets, compounded by $729 million net outflows from U.S. Bitcoin ETFs over two days and rising U.S. Treasury yields hitting 5.31%. Short-term holders also sold 55,600 BTC at a loss during the dip. These events highlight increased volatility and risk in crypto markets, influenced by broader financial conditions.
Bitcoin's recent price drop is context for readers following cryptocurrency markets. For readers following crypto, here is Pluang's market snapshot as of Oct 10, 2026 13:51 WIB: out of 50 major cryptocurrencies priced on Pluang, 32 rose and 17 fell today. Notable movers include EOS at Rp12.649 (+8.13%), DOT at Rp22.459 (+7.35%) with a 31% sell / 69% buy order split, and KSM at Rp90.972 (+5.86%) with a 97% sell / 3% buy order split.
At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...
Bitcoin's price remains stable around $82,500 even as reports emerge about a theft involving Ledger, a popular crypto hardware wallet provider. This resilience suggests investor confidence in Bitcoin's value despite security concerns in the crypto sp...
Bitcoin's price fell from about $85.7K to $82.5K, triggering over $2.4 billion in liquidations mostly on long positions. The decline coincided with rising US Treasury yields above 5.3%, higher oil prices, and significant outflows from Bitcoin ETFs, r...
Bitcoin stabilized around $82,500 following a sharp drop to $80,350 caused by a security exploit involving Ledger hardware wallets. The incident led to over $1 billion in crypto liquidations within 24 hours, shaking investor confidence, especially am...
Entrada Therapeutics is rated Buy with a fair value of $8.50, implying about 52% upside from the current $5.61 price. The company’s Duchenne muscular dystrophy drug ENTR-601-44 showed a disappointing initial increase in dystrophin, but this is attrib...
